EUVIMED · CrossrefJournal
Oncology and Therapy
ISSN 2366-1070 · Springer Science and Business Media LLC
Latest articles
Real-World Risk of Venous Thromboembolism with Bevacizumab Biosimilar versus Reference Biologic in Japanese Patients with Cancer: A Retrospective Cohort Study
From Guidelines to Real Life—Multidisciplinary Insights for Optimizing Intravesical Bacillus Calmette–Guérin (BCG) Therapy in NMIBC
Real-World Treatment Patterns and Unmet Needs of Patients with Locally Advanced Cervical Cancer in Mainland China
Durable Treatment-Free Remission in BRCA1-Associated Metastatic Triple-Negative Breast Cancer with Brain and Radiologically Diagnosed Hepatic Metastases: A Case Report
Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study
Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer
Exploring Patient Perspectives on Upper Tract Urothelial Cancer: A Qualitative Interview Study
First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307
A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas
Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO)
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor® (Mechlorethamine) in the Treatment of CTCL
Telerehabilitation for Pain, Function, and Quality of Life in Patients with Cancer: A Systematic Review
Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture
Occupational Variation in the Incidence of Laryngeal Cancer in the Nordic Countries
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study
Occupational Variation in Thyroid Cancer Incidence in the Nordic Countries
Role and Characteristic of Multidisciplinarity in Hepatocellular Carcinoma Management and Care Pathway Certification: Bottom-Up Approach of the MDT Project in Italy
Association of Variants in Candidate Pharmacogenes with Response to Mercaptopurine and Methotrexate in Pediatric Acute Lymphoblastic Leukemia: A Single-Center Experience from Croatia
Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia
Repurposing Syrosingopine for Cancer Therapy: Lactate Trapping and ISR Sensitization as Metabolic Vulnerabilities
Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy
The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast
Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany
Summary of Research: Elranatamab Fixed Dosing—A Safe, Effective, and Convenient Dosing Approach
Several Considerations on the Pathology, Treatment, and Prognosis of Laryngeal NUT Carcinoma
Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial
Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer
EUVIMED